drugset / Trial / NCT00539253

Assessment of Liver Cancer Response to TACE Using MultiHance-Enhanced MRI.

NCT00539253

NaSingle-groupOpen-labelDiagnostic

Summary

This research is being done to find out if using the contrast agent MultiHance can be used to show how a liver tumor responds to the chemotherapy given during Transcatheter Arterial Chemoembolization (TACE).

Timeline

Start
2007-09
Primary completion
2013-03
Completion
2013-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Gadobenate dimeglumine Diagnostic / imaging agent